NZSE:TRU

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand, Mexico, China, Russia, Zimbabwe, Papua New Guinea, and internationally. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has TruScreen Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRU is more volatile than 90% of NZ stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: TRU's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of NZ stocks.


Market Performance


7 Day Return

-0.7%

TRU

7.1%

NZ Medical Equipment

3.9%

NZ Market


1 Year Return

29.1%

TRU

13.7%

NZ Medical Equipment

10.6%

NZ Market

Return vs Industry: TRU exceeded the NZ Medical Equipment industry which returned 13.7% over the past year.

Return vs Market: TRU exceeded the NZ Market which returned 10.6% over the past year.


Shareholder returns

TRUIndustryMarket
7 Day-0.7%7.1%3.9%
30 Day51.1%0.9%3.2%
90 Day59.6%-1.6%11.0%
1 Year29.1%29.1%15.1%13.7%14.7%10.6%
3 Year-21.1%-21.1%68.6%61.1%56.9%36.1%
5 Year-45.4%-45.4%161.7%141.8%112.7%61.1%

Long-Term Price Volatility Vs. Market

How volatile is TruScreen Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TruScreen Group undervalued compared to its fair value and its price relative to the market?

4.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TRU is unprofitable, so we can't compare its PE Ratio to the XO Medical Equipment industry average.

PE vs Market: TRU is unprofitable, so we can't compare its PE Ratio to the NZ market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRU is good value based on its PB Ratio (4.2x) compared to the XO Medical Equipment industry average (6.8x).


Next Steps

Future Growth

How is TruScreen Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

59.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRU's revenue (36.2% per year) is forecast to grow faster than the NZ market (5.1% per year).

High Growth Revenue: TRU's revenue (36.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRU's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TruScreen Group performed over the past 5 years?

-22.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRU is currently unprofitable.

Growing Profit Margin: TRU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRU is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.

Accelerating Growth: Unable to compare TRU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (41.9%).


Return on Equity

High ROE: TRU has a negative Return on Equity (-51.05%), as it is currently unprofitable.


Next Steps

Financial Health

How is TruScreen Group's financial position?


Financial Position Analysis

Short Term Liabilities: TRU's short term assets (NZ$6.6M) exceed its short term liabilities (NZ$973.3K).

Long Term Liabilities: TRU's short term assets (NZ$6.6M) exceed its long term liabilities (NZ$49.4K).


Debt to Equity History and Analysis

Debt Level: TRU's debt to equity ratio (3.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if TRU's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRU has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TRU has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 1.4% each year.


Next Steps

Dividend

What is TruScreen Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRU's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Victoria Potarina

0.83

Tenure

NZ$308,956

Compensation

Ms. Victoria Potarina is the Chief Executive Officer of TruScreen Group Limited (formerly known as TruScreen Limited) since March 02, 2020. She was Business Unit Director of the UK and Ireland Diabetes Car...


CEO Compensation Analysis

Compensation vs Market: Victoria's total compensation ($USD221.94K) is about average for companies of similar size in the NZ market ($USD232.93K).

Compensation vs Earnings: Insufficient data to compare Victoria's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Victoria Potarina
Chief Executive Officer0.83yrNZ$308.96kno data
Guy Robertson
CFO & Company Secretary2.17yrsNZ$105.45k0.028%
NZ$ 14.8k
Paul Curran
General Manager of Quality & Regulatory Compliance2.5yrsno data0.024%
NZ$ 12.8k
Edmond Capcelea
Chief Technology Officerno datano datano data
Nicole Melia
Manager of Administration & Marketing2.67yrsno datano data
. Phunc
Head of Cancer Departmentno datano datano data
. Chuong
Head of Research & Development and Training Departmentno datano datano data
. Thuy
Head of High Service Gynaecology Examinationno datano datano data

2.3yrs

Average Tenure

Experienced Management: TRU's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anthony Ho
Chairman2.25yrsNZ$178.00k0.99%
NZ$ 522.0k
Neville Hacker
Member of Medical Advisory Boardno datano datano data
Christopher Horn
Independent Non-Executive Director7.17yrsNZ$84.00k0.56%
NZ$ 297.3k
Michael Campion
Chairman of Medical Advisory Board1yrno datano data
Christopher Lawrence
Non-Executive Director3.08yrsNZ$74.00kno data
Juliet Hull
Independent Non-Executive Director0.33yrno datano data

2.3yrs

Average Tenure

Experienced Board: TRU's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TRU insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.5%.


Top Shareholders

Company Information

TruScreen Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TruScreen Group Limited
  • Ticker: TRU
  • Exchange: NZSE
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NZ$52.616m
  • Shares outstanding: 362.87m
  • Website: https://truscreen.com

Location

  • TruScreen Group Limited
  • Equitable House
  • Level 6
  • Auckland
  • 1010
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRUNZSE (New Zealand Stock Exchange)YesOrdinary SharesNZNZDNov 2014
TRUCHIA (Chi-X Australia)YesOrdinary SharesAUAUDNov 2014

Biography

Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in New Zealand, Mexico, China, Russia, Zimbabwe, Papua New Guinea, and intern...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 06:01
End of Day Share Price2021/01/26 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.